Chungbuk National University Hospital
Chungbuk National University Hospital
Cheongju-si, South Korea20 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-10-06 | NCT06635824 | |
| Avelumab Program Rollover Study | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, transitional cell carcinoma, urinary system disorder | Active, not recruiting | Phase 3 | 2026-09-22 | NCT03815643 | |
| Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke | Cerebral Small Vessel Diseases, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Not applicable | 2026-09-11 | NCT06649240 | |
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE | Embolism and Thrombosis, antiphospholipid syndrome, autoimmune disease, brain disorder, brain ischemia, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, immune system disorder, ischemic stroke, nervous system disorder, stroke disorder, thrombotic disease, transient ischemic attack, vascular disorder | Active, not recruiting | Phase 4 | 2026-09-11 | NCT05995600 | |
| Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Not yet recruiting | Not applicable | 2026-08-17 | NCT07741721 | |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2026-08-10 | NCT06731478 | |
| GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, head and neck squamous cell carcinoma, intestinal disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-04 | NCT04083599 | |
| Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium) | central nervous system disorder, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, spinal cord disorder, spinal muscular atrophy | Active, not recruiting | Not stated | 2026-07-27 | NCT04317794 | |
| Evaluation of Effectiveness and Safety of Antegrade and Retrograde Approach of Percutaneous Coronary Intervention for Chronic Total Occlusions | Chronic Total Occlusion of Coronary Artery | Recruiting | Not stated | 2026-06-25 | NCT03667196 | |
| A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervical squamous cell carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, squamous cell carcinoma, squamous cell neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-05-27 | NCT05910827 | |
| The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, brain infarction, brain ischemia, cardiovascular disorder, central nervous system disorder, cerebral infarction, cerebrovascular disorder, ischemic disease, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 4 | 2026-03-27 | NCT06757764 | |
| Study of the Natural History of FFR Guided Percutaneous Coronary Intervention | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Not stated | 2026-03-20 | NCT01366404 | |
| A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2026-02-27 | NCT06532006 | |
| A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421 and DW4421S in Healthy Adult Volunteers | Healthy Adult Volunteer | Enrolling by invitation | Phase 1 | 2026-01-23 | NCT07364877 | |
| A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421-T1 and DW4421S-T1 in Healthy Adult Volunteers | Healthy Adult Volunteer | Not yet recruiting | Phase 1 | 2026-01-23 | NCT07364851 | |
| Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers | Healthy Adult | Not yet recruiting | Phase 1 | 2026-01-20 | NCT07349589 | |
| A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs | Healthy Adult | Recruiting | Phase 1 | 2026-01-15 | NCT07343245 | |
| Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION) | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Phase 4 | 2025-12-31 | NCT05845489 | |
| Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract | Digestive System Diseases, Diverticular Bleeding, Diverticular Diseases, digestive system disorder, gastroenteritis | Not yet recruiting | Not applicable | 2025-04-25 | NCT06939907 | |
| Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD | cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Not applicable | 2025-01-10 | NCT05529459 |